ABSTRACT Aim: Though caffeine is a consolidated treatment in preterm infants, the efficacy and safety of a higher dose have not been systematically appraised.
INTRODUCTION
Very preterm infants are prone to be affected by apnoea of prematurity, which consists of an interruption of breathing for more than 20 seconds leading to reflexive bradycardia and hypoxia. The apnoeic spells occur in 20% of the infants born before gestational week 34, in 85% born before gestational week 30 and in almost all of the infants born before gestational week 28 (1) . The periodic breathing and subsequent hypoxia are harmful for the developing organs and might lead to the need for respiratory support with continuous or intermittent positive airway pressure ventilation (CPAP or IPPV). Both the apnoeic spells and chronic lung disease might constitute risk factors for impaired neurodevelopment (2) . Caffeine has been widely used in neonatal intensive care units (NICU) to treat apnoea of prematurity (3, 4) . The pharmacological effect of caffeine, a methylxanthine, originates from its activity as a nonspecific inhibitor of the adenosine receptors in the central nervous system (5) . The mechanism of caffeine is hypothesised to be due to central stimulation of the respiratory drive through an increased response to high levels of carbon dioxide in the blood, along with direct stimulation of the diaphragm (6). Caffeine is also described to have a diuretic effect, which might be beneficial by removing excess fluids from 
Key notes
Observational studies suggest that maintaining high blood concentrations of caffeine in very preterm infants is associated with improved respiratory outcomes. Evidence from trials seems to suggest that high dose of caffeine might improve short-term respiratory function and reduce bronchopulmonary dysplasia. However, the optimal information size has not been reached. Future trials should ameliorate allocation concealment and outcome reporting. the lungs and facilitating breathing (7) . As enteral absorption of caffeine is high, the same dose is used as for the intravenous administration route (8) . The standard treatment consists of a loading dose 20 mg/kg followed by a maintenance dose 5-10 mg/kg once daily, as used in the caffeine for apnoea of prematurity (CAP) trial (9) . However, the optimal dose of caffeine has not been identified. In terms of duration of hospital stay and overall costs, observational studies have shown that a high dose might be more beneficial (10, 11) . Of note, caffeine levels can be measured with micromethods, thus minimising blood loss and allowing therapeutic drug monitoring (12) . The CAP trial showed that caffeine administration reduced apnoea, bronchopulmonary dysplasia (BPD), cerebral palsy and cognitive delay at 18-21 months as compared with placebo (9, 13) . No safety issues emerged, except a temporary decrease in somatic growth, likely due to increased metabolic work (4, 14) . The neurological benefit of caffeine treatment seemed to be greater among the infants receiving respiratory support (15) . Overall, effects of caffeine appear to be beneficial (16, 17) , including the long-term outcomes (18) (19) (20) . In addition, systematic reviews have shown that caffeine might facilitate the peri-extubation management (21) .
The aim of this systematic review is to assess whether a high-dose caffeine is more effective and safe than low dose for reducing morbidity and mortality in preterm infants.
METHODS
We conducted a systematic review and meta-analysis using the standard methods of the Cochrane Neonatal Review Group. The protocol for this review was registered online prior to commencing data collection and analysis (22) . There was no need for an ethical approval for this study due to the inherent design of a systematic review.
We included randomised controlled trials (RCT) and quasi-RCTs with parallel groups. We excluded any other study types such as crossover trials, cluster trials, observational studies or case reports. We included preterm infants born before gestational week 34 admitted to neonatal intensive care units. High dose was defined as loading dose greater than 20 mg of caffeine citrate/kg body weight/day and maintenance dose as greater than 10 mg of caffeine citrate/kg/day. Low dose was defined as a loading dose equal or less than 20 mg of caffeine citrate/kg/day and maintenance dose equal or less than 10 mg of caffeine citrate/kg/day. We considered loading dose as the very first dose administered, regardless of postnatal age. We classified as high dose the studies where a low loading dose and a high maintenance dose were used. We classified as low dose the studies where a high loading dose and a low maintenance dose were used. Any dose, duration of treatment and timing of initiation have been included. We included three primary outcomes: mortality during the first admission, bronchopulmonary dysplasia at 36 weeks of corrected age (23) and cerebral palsy. The secondary outcomes were as follows: neonatal mortality; severe intraventricular haemorrhage (IVH), ≥grade 3; IVH, any grade; cerebellar haemorrhage; periventricular leukomalacia (PVL); and lesions indicative of brain injury (any lesion detected by ultrasound or magnetic resonance imaging (MRI)). Any brain lesions detected by ultrasound or MRI reported in the studies were summarised for this outcome: apnoea (number of episodes after 24 hours from the beginning of the caffeine treatment); duration of mechanical ventilation (MV); need for MV; need for respiratory support (MV or CPAP); extubation failure (as defined by study authors); retinopathy of prematurity, ≥grade 3; cognitive delay at two years of age; cognitive delay at school age; deafness; blindness; seizure before discharge; seizure after discharge; need for the treatment of patent ductus arteriosus (pharmacological or surgical); any tachycardia; tachycardia, leading to suspension of study intervention; necrotising enterocolitis (NEC); and somatic growth.
We conducted a comprehensive, systematic literature review search in the following databases: The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, issue 3, 2018), MEDLINE (1966 to March 2018) and EMBASE (1988 to March 2018) for eligible trials to be included (Appendix S1). We searched https://clinicaltrials.gov (May 2018) for ongoing trials. No language restrictions were applied.
We assessed methodology regarding blinding of randomisation, intervention and outcome measurements, as well as completeness of follow-up. For categorical and continuous data, the risk ratio (RR) and the mean difference (MD) were calculated, respectively. Ninety-five per cent confidence intervals (CI) were used. Using covidence, two review authors (PB and CR) independently searched and identified eligible trials that met the inclusion criteria. The review authors retrieved the full texts of all potentially relevant articles and independently assessed the eligibility of the studies by filling out eligibility forms designed in accordance with the specified inclusion criteria. We reviewed studies for relevance based on study design, types of participants, interventions and outcome measures. We resolved any disagreements by discussion and, if necessary, by consulting a third review author (MB). The risk of bias was assessed by two authors (PB and CR) independently concerning the seven domains of the Cochrane risk of bias tool (24) . We used a 'Risk of bias' graph to illustrate risk across studies and a summary table for the risk in the individual studies. Any disagreements among the authors regarding the data extraction, data analysis and the risk of bias assessment were solved by discussion and negotiation and ultimately through a third party (MB). We assessed the heterogeneity of the included studies through visual inspection of the forest plots and Higgins I 2 statistics. The Cochrane software RevMan 5.3 (25) was used to synthesise and analyse the data. All infants were analysed on an intention-to-treat basis and with a fixed-effect model. We synthesised the data with risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI). Data reported as median and interquartile range were transformed in mean and standard deviation (26) and pooled in the meta-analysis.
The quality of evidence was assessed through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the GRADE Handbook (27) for the primary outcomes and for severe intraventricular haemorrhage (IVH), cognitive delay, deafness and blindness.
We planned to perform a subgroup analysis for gestational age, the presence of intubation, timing of the intervention and high versus very high dose of caffeine if enough RCTs were included.
RESULTS

Results of the search
Following the literature search and de-duplication, 1798 records were identified. After screening for title and abstract, 18 studies were assessed in full-text format and eight met our eligibility criteria. Two studies were each published as two separate records reporting different outcomes of the same participants and were considered as one study only (28) (29) (30) (31) . Therefore, a total number of six RCTs were included in this systematic review (28, 29, (32) (33) (34) (35) . The PRISMA study flow chart of the search process is presented in Figure 1 . One RCT was not included in the quantitative analysis as it did not report any outcomes that could be pooled in the metaanalysis (33) . We identified one ongoing RCT which was conducted in China (estimated completion date: October 2018) (36) . Detailed descriptions of the six RCTs included are provided in Table 1 and in the Appendix S2.
Two RCTs (28, 34) were conducted in Australia, one (29) in the United States, one (32) in Egypt, one (33) in the UK and one (35) in China. The RCTs included a total of 816 preterm infants. Three of the RCTs enrolled infants born at less than or equal to 32 weeks of gestational age (29, 32, 35) , two enrolled infants born at less than or equal to 31 weeks (33,34) and one infant born at less than 30 weeks of gestational age (28) . The loading dose varied between 80 mg/kg/day and 20 mg/kg/day and the maintenance dose between 20 mg/kg/day and 3 mg/kg day. One study (34) contained three study arms, a very high-dose group (loading dose 60 mg/kg/day and maintenance dose 30 mg/kg/day), a moderately high-dose group (loading dose 30 mg/kg/day and maintenance dose 15 mg/kg/day) and a low-dose group (loading dose 6 mg/kg/day and maintenance dose 3 mg/kg/day). The very high-dose group was not included in the meta-analysis. Similarly, an RCT (33) included a third study arm where infants received theophylline treatment: this group was excluded from our analysis. The study by McPherson and coll. had a different dosage regimen where the infants allocated to high-dose caffeine received a loading dose of 40 mg/kg followed by 20 mg/kg 12 hours later, and then 10 mg/kg at 24 and 36 hours after the initial dose and the low-dose group received a loading dose of 20 mg/kg followed by 10 mg/kg 24 hours after the initial dose (29) . Moreover, maternal age was higher in infants randomised to high-dose caffeine (p = 0.03) (29) . The starting time of caffeine treatment varied across the included studies, with one study evaluating treatment initiated within the first 24 hours of life (29) . In this study, the infants were less mature and of lower birthweight in the high-dose group. In the other studies, the authors stated that there were no imbalances. In the RCT by Gray and coll., 37 infants enrolled in the RCT had caffeine replaced with theophylline after seven days of treatment because of supply problems and were excluded (28) . In addition, another RCT was terminated following the interim analysis when approximately 50% of the a priori calculated sample size had been enrolled (34) . There were no baseline imbalances between intervention and control group in the other two RCTs (32, 35) .
Ten studies were excluded due to not meeting eligibility criteria when screened in full-text format due to the study design (37) (38) (39) (40) (41) (42) , type of comparison (43, 44) or characteristics of the intervention (45, 46) . Figure 2 shows the risk of bias assessment. All RCTs contained an adequate method of randomisation of allocation. However, concealment of allocation was adequate in one study only (32) . One RCT (33) did not use two strengths of caffeine citrate identical in appearance resulting in high risk of bias, whereas the remaining four RCTs did not provide enough information, resulting in an unclear risk of selection bias. The blinding of participants and personnel was satisfactory in all studies except one (33) . The blinding of outcome assessment was not specified in one RCT (33) whereas in another RCT it was described, but not for all outcomes (35) . All studies had low risk of attrition bias. Trial protocols could be found for two RCTs: one RCT reported on all their prespecified outcomes (29) and another did not report on hydrocephalus, thus resulting in an unclear risk of bias (32) . Further, two outcomes were reported but not prespecified. It is however unlikely that this is due to selective reporting. The higher maternal age in the high-dose group in one RCT (29) resulted in an unclear risk of bias ('other bias'). Cognitive delay There was no statistically significant difference between the groups for cognitive delay. Bayley-III scores for cognitive development (high dose 85.6 vs standard dose 88.0, p = 0.42).
Risk of bias in included studies
(
Though some of the studies had an unclear risk of bias, we did not downgrade as it is unlikely this outcome would be affected by this. The number of studies and the overall number of events were small. We downgraded by two levels. Only one study with a small sample size reported this outcome. None of the studies reported on cerebral palsy, neonatal mortality, need for MV, need for respiratory support, cognitive delay at school age and seizure after discharge.
Bold values indicate a statistically significant difference between high and low dose caffeine. This analysis was affected by high heterogeneity (I 2 = 95%) and should be interpreted with caution. An additional study (33) reporting reduction in apnoeic spells in the high-dose group was not pooled in the meta-analysis because data were reported as reduction in events during treatment and not as absolute values.
e This analysis was affected by high heterogeneity (I 2 = 70%) and should be interpreted with caution.
f One study (29) reported Bayley-III scores for cognitive and motor delay at two years of age: high 85.6 vs low dose 88.0 (p = 0.42); high 85.3 vs low dose 85.9 (p = 0.86), respectively. In one study (33) , caffeine dose was adjusted in one infant due to tachycardia. The assessment of the quality of the evidence for the critical outcomes is reported in the Summary of findings table (Table 2) .
Effects of interventions
The effects of high-and low-dose caffeine are shown in Table 3 Forest plots for mortality during the first admission, chronic lung disease, extubation failure, apnoeic spells and duration of mechanical ventilation are depicted in Figures 3-7 , respectively.
None of the studies reported on neonatal mortality; need for MV; need for respiratory support; cognitive delay at school age; and seizure after discharge.
DISCUSSION
Our systematic review included six studies (28, 29, (32) (33) (34) (35) comparing high-and low-dose caffeine, enrolling a total of 816 preterm infants admitted to neonatal intensive care units in different countries. Regarding the primary outcomes of this review, high-dose caffeine was not better than low dose in terms of reducing mortality during the first admission however, may prevent chronic lung disease. Although degree of respiratory morbidity was not different between the two groups, a high-dose caffeine resulted in fewer cases of extubation failure and apnoeas and shorter duration of mechanical ventilation than did low-dose caffeine. However, it should be considered that apnoeic spells are known to be under-reported (47, 48) . In addition, our analyses for apnoea and duration of mechanical ventilation were affected by high heterogeneity (I 2 = 95% and 70%, respectively) and should be interpreted with caution. The quality of evidence for mortality during the first admission, chronic lung disease, extubation failure and apnoeas was rated as low (GRADE) due to imprecision. We identified one ongoing trial (36) . Considering the safety of caffeine treatment, infants receiving high dose had higher rates of tachycardia, however, without leading to discontinuation of caffeine treatment. High dose did not impact on body weight. Taking these outcomes into account, the potential harms might not outweigh the benefits of high-dose caffeine in comparison with low dose. Of note, there was a tendency towards more cases of cerebellar bleeding in the high-dose group than in the lowdose group in one RCT (29) . The infants in this trial received their loading dose caffeine within the first 24 hours of life, when the risk for bleeding is expected to be highest. This may indicate that high-dose caffeine treatment should not be started within the first few days of life.
The present review did not achieve the required information size for any of the outcomes. We could not perform subgroup analysis which was specified a priori (gestational age; intubated vs nonintubated infants; aim and timing of the intervention; dosage) due to the paucity of the included trials. The definition of some outcomes differed among the included studies (e.g. extubation failure), thus potentially affecting the effect estimate.
We rated the overall quality of body of the evidence for this research question as low. This was mainly due to the presence of imprecision due to the paucity of included studies enrolling few infants (n = 816). This is reflected in the wide confidence intervals. Although the risk of bias was unclear for some of the domains (e.g. unsatisfactory allocation concealment), we considered it unlikely that this might have affected the critical outcomes, that is mortality, chronic lung disease and severe IVH. Therefore, we did not further downgrade the certainty of evidence.
The strengths of our analysis include the broad and complete search strategy. In contrast to other systematic reviews on the same topic (49,50), we are confident that we succeeded to identify all relevant studies comparing highand low-dose caffeine in preterm infants. Vliegenthart et al. (49) did not specify high and low dose and pooled results regardless of dose, resulting in that what was considered as high-dose caffeine in one trial (51) was equal to or lower than low dose in another trial (28, 29, 32, 33) . Additionally, no review protocol was registered a priori and they failed to retrieve one randomised controlled trial (35) published in Chinese, despite stating that no language restriction was applied (49) . Further, Pakvasa et al. managed to identify three randomised controlled trials (50) . Our prespecified definition of high-and low-dose caffeine resulted in the exclusion of one randomised controlled trial comparing high and low dose (51) . Of note, the high dose in this trial corresponds to low dose according to our definition. We applied no language restriction and succeeded to translate one eligible study from Chinese to English. We published the study protocol for the review in advance which is available online. This was made in order to reduce the risk of bias in the review process, for example to prevent us from making decisions influenced by our findings and to be transparent with our methods and choice of eligibility criteria. Four secondary outcomes were added a posteriori, that is somatic growth, major disabilities, success of ventilator removal and any tachycardia.
In summary, this systematic review showed that a highdose caffeine was more effective for improving short-term respiratory outcomes and did not have relevant side effects as compared with a low dose. However, high dose did not reduce mortality or improve clinically robust outcomes. Due to the limited number of studies, we are far from the optimal information size and the quality of the body of evidence is too low to allow any firm conclusion. Future trials with larger sample sizes should ameliorate allocation concealment and outcome reporting, including cerebral palsy.
